About benralizum ab
Interleukin-5 receptor monoclonal antibody
Used for
- Add-on maintenance treatment for severe eosinophilic asthma in adults and children aged 6 years and older.
Usual adult dose
For asthma: inject 30 mg under the skin every 4 weeks for 3 doses, then every 8 weeks.
Usual dose in children
For asthma, ages 6–11: under 35 kg, 10 mg every 4 weeks for 3 doses, then every 8 weeks; 35 kg or more, 30 mg on the adult schedule.
Common side effects
- Headache
- Sore throat
- Injection-site reactions
- Fever
Important warnings
- Not for treating sudden asthma attacks; continue prescribed inhalers.
- Serious allergic reactions can occur, including delayed reactions.
- Treat existing worm infections before starting; treatment may affect parasite defenses.
- Do not stop inhaled or oral steroids suddenly.
Pregnancy
Human pregnancy information is limited. Use only when potential benefit justifies potential risk; discuss with a healthcare professional.
Breastfeeding
It is unknown whether benralizumab passes into human milk. Consider benefits of breastfeeding and treatment when deciding.
Interactions
- No specific drug interactions are established; formal interaction studies are limited.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.